Tyropanoic acid
Appearance
![]() | |
![]() | |
Names | |
---|---|
Preferred IUPAC name
2-[(3-Butanamido-2,4,6-triiodophenyl)methyl]butanoic acid | |
Other names
2-(3-Butyramido-2,4,6-triiodobenzyl)butanoic acid
2-[[2,4,6-Triiodo-3-(1-oxobutylamino)phenyl]methyl]butanoic acid | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.043.976 |
EC Number |
|
KEGG | |
MeSH | D014441 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C15H18I3NO3 | |
Molar mass | 641.02 g/mol |
Pharmacology | |
V08AC09 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Tyropanoic acid and its salt sodium tyropanoate are radiocontrast agents used in cholecystography (X-ray diagnosis of gallstones). Trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.[1] This molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones to produce a visible image. After injection it is rapidly excreted into the bile.[2]
References
- ^ "PubChem CID 5611".
- ^ Felicetta, James V.; Green, William L.; Nelp, Wil B. (May 1980). "Inhibition of hepatic binding of thyroxine by cholecystographic agents". J. Clin. Invest. 65 (5): 1032–40. doi:10.1172/JCI109755. PMC 371433. PMID 7364937.